Biomarkers
Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review)
International Journal of Oncology 2025 March [Link] Dimitrios Andreikos, Demetrios A Spandidos, Vasiliki Epameinondas Georgakopoulou Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer linked to asbestos exposure and characterized by advanced‑stage disease at presentation. Despite advances in treatment, prognosis remains abysmal, highlighting the imperative for the development of novel biomarkers and treatment approaches.…
Read MoreThe phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes
Journal of Translational Medicine 2025 February 20 [Link] Federica Torricelli, Filomena Spada, Cynthia Bishop, Katrina Todd, Daisuke Nonaka, Nedyalko Petrov, Manuela Terranova Barberio, Alan G Ramsay, Richard Ellis, Alessia Ciarrocchi, Benedetta Apollonio, Andrea Billè Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options. To improve patients management and…
Read MorePotential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MoreThe Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
Medicina 2025 January 16 [Link] Nadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, Delyadil Karakaş Kılıç, Esra Zeynelgil, Yunus Emre Altintaş, Berivan Deniz Çimik, Yeşim Ağyol, Ali Kaan Güren, Pınar Erel, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Abdussamet Çelebi, Nazım Can Demircan, Selver Işık, Rukiye Arıkan, Murat Araz, Serdar Karakaya, Murat Sarı, Osman Köstek, İbrahim…
Read MorePreclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma
Marine Drugs 2025 January 10 [Link] Angélica Luna-Nophal, Fernando Díaz-Castillo, Vanessa Izquierdo-Sánchez, Jesús B Velázquez-Fernández, Mario Orozco-Morales, Luis Lara-Mejía, Johana Bernáldez-Sarabia, Noemí Sánchez-Campos, Oscar Arrieta, José Díaz-Chávez, Jorge-Ismael Castañeda-Sánchez, Alexei-Fedorovish Licea-Navarro, Saé Muñiz-Hernández Abstract Malignant pleural mesothelioma (MPM) is a rare neoplasm with increasing incidence and mortality rates. Although recent advances have improved the overall…
Read MoreAmerican Association of Bronchology and Interventional Pulmonology Essential Knowledge in Interventional Pulmonology Series: Selected Topics in Malignant Pleural Disease
Journal of Bronchology and Interventional Pulmonology 2024 December 20 [Link] Ara A Chrissian, Hatoon Abbas, Udit Chaddha, Labib G Debiane, Erin DeBiasi, Darius Filsoof, Muhammad Daniyal Hashmi, Christopher Morton, Warren C Naselsky, Jasleen Pannu, Reza Ronaghi, Bertin D Salguero, Cristina Salmon, Shelby J Stewart, Colleen L Channick Abstract The goal of the American Association of…
Read MoreTEAD-independent cell growth of Hippo-inactive mesothelioma cells: Unveiling resistance to TEAD inhibitor K-975 through MYC signaling activation
Molecular Cancer Therapeutics 2024 December 17 [Link] Ken Akao, Tatsuhiro Sato, Emi Mishiro-Sato, Satomi Mukai, Farhana Ishrat Ghani, Lisa Kondo-Ida, Kazuyoshi Imaizumi, Yoshitaka Sekido Abstract Inactivation of the Hippo tumor suppressive pathway is frequently observed in mesothelioma, which leads to the activation of YAP and TAZ (YAP/TAZ) transcriptional coactivators. YAP/TAZ form complexes with TEAD family…
Read MoreSerum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Frontiers in Immunology 2024 December 2 [Link] Saima Jamil Farooqi, Zhi Zhao, Åsa Kristina Öjlert, Solfrid Thunold, Hedvig Vidarsdotter Juul, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Hanne Marte Gjertsen Nymoen, Åslaug Helland, Vilde Drageset Haakensen Abstract Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival,…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 204 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read More